A meta-analysis of double-blind, randomized controlled trials examined adverse effects attributed to statins based on product label information. Study results do not support a causal link between statin therapy and most of the conditions listed as potential side effects on product labels, including cognitive impairment, depression, sleep disorders, and peripheral neuropathy. Thus, data from blinded randomized trials do not suggest that these conditions are caused by statins to the extent that product labeling might suggest. The authors of the study recommend a review of such labels and other official sources of health information. The goal is to enable patients and their doctors to make decisions about statin treatment based on accurate and verified information. These findings are important for a proper understanding of the safety of statins and for increasing patient confidence in this treatment.